title: FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
abstract: An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01-0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.
authors.affiliation: a Department of Radiology , The Mount Sinai Hospital , New York , NY , USA.
authors.forename: Lale
authors.initials: L
authors.lastname: Kostakoglu
authors.affiliation: b John Theurer Cancer Center HUMC , Hackensack , NJ , USA.
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
authors.affiliation: c Department of Haematology-Oncology , IEO Istituto Europeo di Oncologia , Milano , Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.affiliation: d Hematology Department , University Hospital of Salamanca , Salamanca , Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.affiliation: e Princess Margaret Hospital, University of Toronto , ON , Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Crump
authors.affiliation: f Division of Hematology, Department of Translational Medicine , Amedeo Avogadro University of Eastern Piedmont , Novara , Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.affiliation: g Division of Medical Oncology , Kingston General Hospital, Queen's University , Kingston , ON , Canada.
authors.forename: Tara
authors.initials: T
authors.lastname: Baetz
authors.affiliation: h Sunnybrook Health Sciences Center , Toronto , ON , Canada.
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.affiliation: i Genentech Inc , South San Francisco , CA , USA.
authors.forename: Gregg
authors.initials: G
authors.lastname: Fine
authors.affiliation: j F. Hoffmann-La Roche , Basel , Switzerland.
authors.forename: Guenter
authors.initials: G
authors.lastname: Fingerle-Rowson
authors.affiliation: j F. Hoffmann-La Roche , Basel , Switzerland.
authors.forename: Claude
authors.initials: C
authors.lastname: Berge
authors.affiliation: j F. Hoffmann-La Roche , Basel , Switzerland.
authors.forename: Deniz
authors.initials: D
authors.lastname: Sahin
authors.affiliation: k Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Press
authors.affiliation: l Centre for Lymphoid Cancer, British Columbia Cancer Agency , Vancouver , BC , Canada.
authors.forename: Laurie
authors.initials: L
authors.lastname: Sehn
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography; D049268:Positron-Emission Tomography; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: FDG PET/CT; follicular lymphoma; prediction of response; relapse